475 related articles for article (PubMed ID: 21415162)
1. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH
Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
Vlahiotis A; Devine ST; Eichholz J; Kautzner A
J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
[TBL] [Abstract][Full Text] [Related]
4. Comment: economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
Simoens S
Ann Pharmacother; 2011 Sep; 45(9):1169-70. PubMed ID: 21852600
[No Abstract] [Full Text] [Related]
5. Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons.
Wu EQ; Ben-Hamadi R; Yu AP; Tang J; Haim Erder M; Bose A
J Med Econ; 2010; 13(2):314-23. PubMed ID: 20504111
[TBL] [Abstract][Full Text] [Related]
6. Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.
Zhou ZY; Sun S; Chopra P; Zhong Y; Totev T; Signorovitch J
J Med Econ; 2015; 18(11):919-29. PubMed ID: 26121061
[TBL] [Abstract][Full Text] [Related]
7. Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder.
Leelahanaj T
J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S35-42. PubMed ID: 21284135
[TBL] [Abstract][Full Text] [Related]
8. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.
Wu E; Greenberg P; Yang E; Yu A; Ben-Hamadi R; Erder MH
Curr Med Res Opin; 2008 Oct; 24(10):2805-13. PubMed ID: 18755054
[TBL] [Abstract][Full Text] [Related]
9. An Evaluation of Health Service Impacts Consequent to Switching from Brand to Generic Venlafaxine in New Zealand under Conditions of Price Neutrality.
Lessing C; Ashton T; Davis P
Value Health; 2015 Jul; 18(5):646-54. PubMed ID: 26297093
[TBL] [Abstract][Full Text] [Related]
10. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs.
Wu EQ; Greenberg PE; Yang E; Yu AP; Ben-Hamadi R; Erder MH
J Med Econ; 2009 Jun; 12(2):124-35. PubMed ID: 19566483
[TBL] [Abstract][Full Text] [Related]
11. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Shih YC; Bekele NB; Xu Y
Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
[TBL] [Abstract][Full Text] [Related]
12. Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a medicaid population.
Wu EQ; Ben-Hamadi R; Lu M; Beaulieu N; Yu AP; Erder MH
Manag Care; 2012 Jan; 21(1):49-58. PubMed ID: 22332457
[TBL] [Abstract][Full Text] [Related]
13. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.
Panzer PE; Regan TS; Chiao E; Sarnes MW
Am J Manag Care; 2005 Oct; 11(12 Suppl):S370-9. PubMed ID: 16236019
[TBL] [Abstract][Full Text] [Related]
14. A budget-impact and cost-effectiveness model for second-line treatment of major depression.
Malone DC
J Manag Care Pharm; 2007 Jul; 13(6 Suppl A):S8-18. PubMed ID: 17874482
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on the pharmacoeconomics of escitalopram in depression.
Croom KF; Plosker GL
CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
[TBL] [Abstract][Full Text] [Related]
18. Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK.
Wade AG; Saragoussi D; Despiégel N; François C; Guelfucci F; Toumi M
Curr Med Res Opin; 2010 May; 26(5):1161-70. PubMed ID: 20297951
[TBL] [Abstract][Full Text] [Related]
19. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.
Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
Adv Ther; 2013 Jul; 30(7):697-712. PubMed ID: 23929174
[TBL] [Abstract][Full Text] [Related]
20. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
